Pathophysiology, Investigations, and Treatment in Patients with Hydatidiform Mole
Omar Elsaka *
Mansoura Manchester Medical Program (MMMP), Department of Gynecology and Obstetrics, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Moneer Ayman Noureldean
Mansoura Manchester Medical Program (MMMP), Department of Gynecology and Obstetrics, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Mohamed Adel Gamil
Mansoura Manchester Medical Program (MMMP), Department of Gynecology and Obstetrics, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Mostafa Tarek Ghazali
Mansoura Manchester Medical Program (MMMP), Department of Gynecology and Obstetrics, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Ashraf Hamada Abd Al-Razik
Mansoura Manchester Medical Program (MMMP), Department of Gynecology and Obstetrics, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Dalia Hisham
Mansoura Manchester Medical Program (MMMP), Department of Gynecology and Obstetrics, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
*Author to whom correspondence should be addressed.
Abstract
Background: A hydatiform mole (sometimes called a molar pregnancy) is a type of Gestational Trophoblastic Disease (GTD) that starts in the placenta and can spread. The tumor arises from prenatal tissue rather than maternal tissue, which makes it distinctive. Hydatiform moles (HM) are divided into two types: total and partial. They are the noninvasive form of gestational trophoblastic illness. While hydatiform moles are usually considered benign, they are premalignant and can develop into malignant and invasive moles. This activity discusses the pathophysiology, examination, and treatment of hydatiform moles, as well as the role of the interprofessional team in inpatient care.
Conclusion: The goal of this review article is to identify the etiology of a hydatiform mole, describe the presentation of a patient with a hydatiform mole, review the treatment and management options for hydatiform moles, and explain interprofessional team strategies for improving care coordination and communication to advance the treatment of hydatiform moles and improve outcomes.
Keywords: Choriocarcinoma, fertilization, hydatidiform mole, invasive mole, trophoblast
How to Cite
Downloads
References
Agarwal R, Teoh S, Short D, et al. Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study. Lancet. 2012;379(9811):130-5.
Andreasen L, Christiansen OB, Niemann I, Bolund L, Sunde L. NLRP7 or KHDC3L genes and the etiology of molar pregnancies and recurrent miscarriage. Mol Hum Reprod. 2013;(11):773-81.
Batorfi J, Vegh G, Szepesi J, et al. How long should patients be followed after molar pregnancy? Analysis of serum hCG follow-up data. Eur J Obstet Gynecol Reprod Biol. 2004;112(1):95-7.
Cheung AN, Khoo US, Lai CY, et al. Metastatic trophoblastic disease after an initial diagnosis of partial hydatidiform mole: genotyping and chromosome in situ hybridization analysis. Cancer. 2004; 100(7):1411-7.
Coyle C, Short D, Jackson L, Sebire NJ, Kaur B, Harvey R, et al. What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients. Gynecol Oncol. 2018;148(2):254-257.
Deveault C, Qian JH, Chebaro W, et al. NLRP7 mutations in women with diploid androgenetic and triploid moles: a proposed mechanism for mole formation. Hum Mol Genet. 2009;18(5): 888-97.
Fallahian M. Familial gestational trophoblastic disease. Placenta. 2003; 24(7):797-9.
Feltmate CM, Batorfi J, Fulop V, et al. Human chorionic gonadotropin follow-up in patients with molar pregnancy: a time for reevaluation. Obstet Gynecol. 2003; 101(4):732-6.
Florio P, Severi FM, Cobellis L, et al. Serum activin A and inhibin A. New clinical markers for hydatidiform mole. Cancer. 2002;94(10):2618-22.
Fukunaga M. Immunohistochemical characterization of p57(KIP2) expression in early hydatidiform moles. Hum Pathol. 2002;33(12):1188-92.
Fulop V, Mok SC, Berkowitz RS. Molecular biology of gestational trophoblastic neoplasia: a review. J Reprod Med. 2004; 49(6):415-22.
Gadducci A, Cosio S, Fanucchi A, et al. Prognosis of Patients with Gestational Trophoblastic Neoplasia and Obstetric Outcomes of Those Conceiving After Chemotherapy. Anticancer Res. 2016;36 (7):3477-82.
Genest DR, Dorfman DM, Castrillon DH. Ploidy and imprinting in hydatidiform moles. Complementary use of flow cytometry and immunohistochemistry of the imprinted gene product p57KIP2 to assist molar classification. J Reprod Med. 2002;47(5):342-6.
Hodges MD, Rees HC, Seckl MJ, et al. Genetic refinement and physical mapping of a biparental complete hydatidiform mole locus on chromosome 19q13.4. J Med Genet. 2003;40(8):e95.
Horowitz NS, Berkowitz RS, Elias KM. Considering changes in the recommended human chorionic gonadotropin monitoring after molar evacuation. Obstet Gynecol. 2020;135(1):9-11.
Hurteau JA. Gestational trophoblastic disease: management of hydatidiform mole. Clin Obstet Gynecol. 2003;46(3): 557-69.
Joneborg U, Eloranta S, Johansson AL, Marions L, Weibull CE, Lambe M. Hydatidiform mole and subsequent pregnancy outcome: a population-based cohort study. Am J Obstet Gynecol. 2014; 211(6):681.e1-7.
Mangili G, Garavaglia E, Cavoretto P, Gentile C, Scarfone G, Rabaiotti E. Clinical presentation of hydatidiform mole in northern Italy: has it changed in the last 20 years?. Am J Obstet Gynecol. 2008; 198(3):302.e1-4.
Melamed A, Gockley AA, Joseph NT, Sun SY, Clapp MA, Goldstein DP, et al. Effect of race/ethnicity on risk of complete and partial molar pregnancy after adjustment for age. Gynecol Oncol. 2016;143(1):73-76.
Sebire NJ, Fisher RA, Foskett M, et al. Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy. BJOG. 2003;110(1): 22-6.
Sebire NJ, Foskett M, Short D, et al. Shortened duration of human chorionic gonadotrophin surveillance following complete or partial hydatidiform mole: evidence for revised protocol of a UK regional trophoblastic disease unit. BJOG. 2007;114(6):760-2.
Slim R, Mehio A. The genetics of hydatidiform moles: new lights on an ancient disease. Clin Genet. 2007; 71(1):25-34.
Soto-Wright V, Bernstein M, Goldstein DP, Berkowitz RS. The changing clinical presentation of complete molar pregnancy. Obstet Gynecol. 1995;86(5):775-9.
Sun SY, Melamed A, Goldstein DP, et al. Changing presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: does early diagnosis alter risk for gestational trophoblastic neoplasia?. Gynecol Oncol. 2015;138(1): 46-9.
Thaker HM, Berlin A, Tycko B, et al. Immunohistochemistry for the imprinted gene product IPL/PHLDA2 for facilitating the differential diagnosis of complete hydatidiform mole. J Reprod Med. 2004; 49(8):630-6.
Vargas R, Barroilhet LM, Esselen K, et al. Subsequent pregnancy outcomes after complete and partial molar pregnancy, recurrent molar pregnancy, and gestational trophoblastic neoplasia: an update from the New England Trophoblastic Disease Center. J Reprod Med. 2014;59(5-6):188-94.
Watson EJ, Hernandez E, Miyazawa K. Partial hydatidiform moles: a review. Obstet Gynecol Surv. 1987; 42(9):540-4.
Zhao P, Chen Q, Lu W. Comparison of different therapeutic strategies for complete hydatidiform mole in women at least 40 years old: a retrospective cohort study. BMC Cancer. 2017;17(1):733.